News | May 12, 2010

Highly Conformal IMRT Reduces Side Effects in Head and Neck

May 12, 2010 - This year, 35,720 Americans will be diagnosed with head and neck cancer, and 7,600 will die from the disease, according to the American Cancer Society.

To better manage the disease, researchers at the University of Michigan (U-M) Comprehensive Cancer Center have applied advanced radiation techniques for head and neck cancer to avoid treating critical structures that affect swallowing and eating. These principles and techniques treated the cancer effectively while greatly reducing long-term swallowing complications, according to the study published in Journal of Clinical Oncology.

The researchers applied highly conformal, intensity-modulated radiation therapy (IMRT) and knowledge of the anatomy and physiology of the structures involved to carefully craft a novel treatment plan that avoids certain muscles in the mouth and throat that are most involved in swallowing. Generally, head and neck tumors do not spread to these structures.

Of the 73 patients treated with this technique, all but four were eating a normal diet after their treatment ended and only one was dependent on a feeding tube. Typically up to 20 percent of head and neck cancer patients remain dependent on a feeding tube after finishing an intensive course of radiation treatment concurrent with chemotherapy.

"More aggressive treatments for head and neck cancer have improved cancer control, but at the expense of quality of life. In this study, we did not compromise tumor control and we were able to improve this important quality of life measure," said study author Avraham Eisbruch, M.D., professor of radiation oncology at the U-M Medical School.

Scar tissue from radiation treatments to the head and neck often creates long-term problems with swallowing and eating solid foods, which does not improve over time. In this study, 29 percent of the patients required a temporary feeding tube during treatment because of pain while swallowing. But by one year after treatment, only one of the 73 patients on the study still required a feeding tube. Questionnaires to assess eating and swallowing function showed that on average, patients had only slight difficulties up to two years after treatment.

No patients had a spread of their cancer to the untreated structures and few cancers recurred overall, suggesting it was not harmful to avoid treating these areas. After three years, 88 percent of patients were cancer-free.

Eisbruch and his colleagues were also leaders in pioneering head and neck radiation treatments that avoid the salivary glands, reducing significantly the severity of permanently dry mouth, which has previously been a major complication of radiotherapy for head and neck cancer.

"We seek a cure for these patients, but we also seek quality of life. As cure rates have improved in recent years, quality of life issues become more and more important. Our next steps are to identify which patients are likely to do well with treatment and reduce the intensity of treatment to limit the burden of these side effects," Eisbruch said.

Methodology: The study looked at 73 patients with stage III or stage IV oropharyngeal cancer, including cancer of the tonsils or the base of the tongue. Patients were treated with seven weeks of daily intensity-modulated radiation therapy to the neck, designed to avoid the swallowing structures. Chemotherapy was administered weekly during this time. Patients were assessed with videofluoroscopy, an imaging procedure, periodically during treatment and up to two years after to assess swallowing. Swallowing was also assessed by doctors and through patient report using standard questionnaires.

Additional U-M authors: Felix Y. Feng, M.D.; Hyungjin M. Kim, Sc.D.; Teresa H. Lyden, M.A.; Marc J. Haxer, M.A.; Francis P. Worden, M.D.; Mary Feng, M.D.; Jeffrey S. Moyer, M.D.; Mark E. Prince, M.D.; Thomas E. Carey, Ph.D.; Gregory T. Wolf, M.D.; Carol R. Bradford, M.D.; Douglas B. Chepeha, M.D.
Funding: National Institutes of Health, Newman Family Foundation

For more information: jco.ascopubs.org

Related Content

Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

Feature | Radiation Oncology | November 06, 2018 | By Greg Freiherr
Approximately 11,000 professionals attended the four-day meeting of the...